By NewsDesk @infectiousdiseasenews
In late December 2019, antibiotic development and commercialization company, Melinta Therapeutics, Inc. initiated a voluntary Chapter 11 process to effectuate restructuring transaction while continuing normal-course operations.
This caused a ripple effect of concern in the medical and public community. This followed just six months after Achaogen filed for bankruptcy.
In this video, I take a look at this important issue, some experts thoughts on how to address it and a Senate bill that hasn’t gone far in 6 months.